• KOL
    • Angina Pectoris
    • William H Frishman
    • William H Frishman: Influence Statistics

      William H Frishman

      William H Frishman

      Show email address

      Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY. | Department of Cardiology, Westchester Medical Center, Valhalla, NY. | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      William H Frishman:Expert Impact

      Concepts for whichWilliam H Frishmanhas direct influence:Angina pectoris,Heart failure,Cardiovascular disease,Myocardial infarction,Systemic hypertension,United states,Blood pressure,Calcium antagonists.

      William H Frishman:KOL impact

      Concepts related to the work of other authors for whichfor which William H Frishman has influence:Heart failure,Blood pressure,Myocardial infarction,Cardiovascular disease,Cardiogenic shock,Atrial fibrillation,Angina pectoris.

      KOL Resume for William H Frishman

      Year
      2022

      Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.

      2021

      Department of Medicine and Cardiology, New York Medicine and Westchester Medical Center, Valhalla, NY.

      New York Medical College School of Medicine Westchester Medical Center Healthcare System Valhalla; Supplements Editor, The American Journal of Medicine. Electronic address:

      2020

      Department of Medicine, Westchester Medical Center, New York Medical College, 100 Woods Road, Valhalla, NY 10595, USA

      New York Medical College/Westchester Medical Center, Valhalla, NY.

      2019

      Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York

      2018

      New York Medical College

      2017

      Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla

      2016

      New York Medical College, Valhalla, NY

      2015

      Division of Cardiology, New York Medical College, Valhalla, New York

      2014

      From the *Department of Medicine, and †Department of Medicine, Division of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, New York.

      Department of Medicine, New York Medical College, New York, NY

      2013

      From the Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY and Department of Medicine, Phelps Memorial Hospital Center, Sleepy Hollow, NY.

      Professor of Medicine, Associate Dean for Clinical/Translational Research, Harvard Medical School, Senior Investigator, TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts

      Department of Medicine, Division of Cardiology, New York Medical College, Valhalla, NY, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which William H Frishman is among the top experts in the world.
      Concept World rank
      cns ketanserin #1
      betaadrenergic blockers angiotensin #1
      dilevalol atenolol #1
      fda hypertension #1
      persistent lvh baseline #1
      subjects transient episodes #1
      new beta #1
      systemic hypertension htn #1
      ketanserin responders #1
      calcium inhibitor #1
      mild‐to‐moderate hypertension #1
      postulated involvement calcium #1
      effects combination treatment #1
      labetalol therapy #1
      colchicine darapladib #1
      infarction adrenergic #1
      bepridil frequency #1
      viral autoimmune myocarditis #1
      treatment systemic hypertension #1
      inflammatory medications methotrexate #1
      betablockers mortality risk #1
      drug therapy basis #1
      placebo labetalol therapy #1
      chd vaccines coronary #1
      angina total work #1
      janus kinase monoclonal #1
      studies lv function #1
      concomitant angina pectoris #1
      heart rate diltiazem #1
      humans patient protection #1
      subjects new lvh #1
      older hospitalized arrhythmias #1
      drugs statin class #1
      placebo nonelderly patients #1
      agents nitrates #1
      549 patients #1
      radionuclide ventriculography ventriculography #1
      vasodilators2see #1
      vasodilators detection #1
      hiv infection heart #1
      anemia hypocholesterolemia #1
      dilevalol patients #1
      combined ihd hypertension #1
      calciuminhibiting drugs treatment #1
      dilevalol compared #1
      aged atenolol atenolol #1
      summaryβblockers #1
      purines pyrazoles monoclonal #1
      cad ecg evidence #1
      systemic hypertension nifedipine #1
      Sign-in to see all concepts, it's free!

      Prominent publications by William H Frishman

      Bevantolol


      [ PUBLICATION ]
      KOL-Index: 42778

      SynopsisBevantolol is a new β- adrenoceptor antagonist which possesses a relatively high degree of selectivity for β1- adrenoceptors. It is devoid of intrinsic sympathomimetic activity and possesses only weak local anaesthetic properties. Interestingly, bevantolol has been shown to cause a lowering effect on peripheral vascular resistance. Available clinical data indicate that bevantolol, given once or twice daily, is an effective agent in the management of mild to moderate hypertension ...

      Known for Atenolol Bevantolol | Treatment Hypertension | Oral Administration | Adrenergic Beta | Peripheral Resistance
      KOL-Index: 16220

      BACKGROUND: Older women presenting with ST-segment elevation myocardial infarction (STEMI) are less likely to receive revascularization and have worse outcomes relative to their male counterparts.

      OBJECTIVES: This study sought to determine temporal trends and sex differences in revascularization and in-hospital outcomes of younger patients with STEMI.

      METHODS: We used the 2004 to 2011 Nationwide Inpatient Sample databases to identify all patients age 18 to 59 years hospitalized with ...

      Known for Temporal Trends | United States | Younger Women | Stemi Hospital | Myocardial Infarction
      KOL-Index: 16009

      BACKGROUND: Regional differences in the treatment and outcomes of patients with ST-elevation myocardial infarction (STEMI) within the United States remain poorly understood.

      HYPOTHESIS: Treatment choice and outcomes in patients with STEMI differ between regions within the United States.

      METHODS: We used the 2003 to 2010 Nationwide Inpatient Sample databases to identify all patients age ≥ 40 years hospitalized with STEMI. Patients were divided into 4 groups according to region: Northeast, ...

      Known for United States | Regional Variation | Myocardial Infarction | Midwest West | Patients Stemi
      KOL-Index: 15662

      The efficacy and safety of oral nifedipine and diltiazem were compared in 20 patients with stable angina pectoris with use of a placebo run-in, randomized, double-blind titration to maximal effect crossover protocol. The effects of treatment withdrawal were also analyzed. All patients received placebo for 2 weeks and were then randomly assigned to receive either diltiazem or nifedipine. A 2 week drug titration phase in which patients received either diltiazem (180 to 360 mg/day) or ...

      Known for Nifedipine Diltiazem | Angina Pectoris | Exercise Tolerance | Segment Depression | Hemodynamics Humans
      KOL-Index: 15505

      BACKGROUND: Limited information is available on the contemporary and potentially changing trends in the incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction (STEMI).

      METHODS AND RESULTS: We queried the 2003-2010 Nationwide Inpatient Sample databases to identify all patients ≥ 40 years of age with STEMI and cardiogenic shock. Overall and age-, sex-, and race/ethnicity-specific trends in incidence of cardiogenic shock, early mechanical ...

      Known for Cardiogenic Shock | United States | Patients Stemi | Myocardial Infarction | Inhospital Mortality
      KOL-Index: 14478

      In a randomized, double-blind, placebo-controlled crossover trial, diltiazem and nifedipine were compared in 10 patients with stable angina pectoris and mild to moderate hypertension (supine diastolic blood pressure greater than or equal to 90 mm Hg). Patients received placebo for 2 weeks, then increasing doses of diltiazem (90 to 360 mg/day) or nifedipine (30 to 120 mg/day) in 3 daily divided doses over 2 weeks, followed by 1 week of therapy at the maximal dose, a 1-week placebo ...

      Known for Angina Pectoris | Diltiazem Nifedipine | Heart Rate | Blood Pressure | 2 Weeks
      KOL-Index: 14367

      BACKGROUND: The association of chronic renal insufficiency with outcomes after percutaneous coronary intervention (PCI) in the current era of drug-eluting stents and modern antithrombotic therapy has not been well characterized.

      METHODS AND RESULTS: We queried the 2007-2011 Nationwide Inpatient Sample databases to identify all patients aged ≥18 years who underwent PCI. Multivariable logistic regression was used to compare in-hospital outcomes among patients with chronic kidney disease ...

      Known for Patients Ckd | Renal Insufficiency | Percutaneous Coronary | Hospital Outcomes | Chronic Length
      KOL-Index: 14309

      BACKGROUND: Regional variation in the incidence and outcomes of in-hospital cardiac arrest (IHCA) is not well studied and may have important health and policy implications.

      METHODS AND RESULTS: We used the 2003 to 2011 Nationwide Inpatient Sample databases to identify patients≥18 years of age who underwent cardiopulmonary resuscitation (International Classification of Diseases, Ninth Edition, Clinical Modification procedure codes 99.60 and 99.63) for IHCA. Regional differences in IHCA ...

      Known for United States | Regional Variation | Outcomes Ihca | Northeast Midwest | International Classification
      KOL-Index: 13820

      BACKGROUND: There has been a paradigm shift in the definition of timing of early invasive strategy (EIS) for patients admitted with non-ST-elevation myocardial infarction (NSTEMI) in the last decade. Data on trends of EIS for NSTEMI and associated in-hospital outcomes are limited. Our aim is to analyze temporal trends in the incidence, utilization of early invasive strategy, and in-hospital outcomes of NSTEMI in the United States.

      METHODS AND RESULTS: We analyzed the 2002-2011 Nationwide ...

      Known for United States | Early Invasive Strategy | Myocardial Infarction | Nstemi Hospital | Temporal Trends
      KOL-Index: 13600

      BACKGROUND: The optimal revascularization strategy in patients with multivessel disease presenting with cardiogenic shock complicating ST-segment-elevation myocardial infarction remains unknown.

      METHODS AND RESULTS: Databases were searched from 1999 to October 2016. Studies comparing immediate/single-stage multivessel percutaneous coronary intervention (MV-PCI) versus culprit vessel-only PCI (CO-PCI) in patients with multivessel disease, ST-segment-elevation myocardial infarction, and ...

      Known for Elevation Myocardial | Cardiogenic Shock | Culprit Vessel | Pci Patients | Coronary Intervention
      KOL-Index: 13580

      The effects of oral labetalol, an alpha-beta adrenoceptor blocker, were evaluated in 10 patients with angina pectoris and hypertension. After 3 weeks of placebo, increasing doses of labetalol (300 to 1,200 mg/day) were given over 4 weeks followed by a rapid drug withdrawal phase. The frequency of anginal attacks and exercise tolerance were measured as were noninvasive indexes of left ventricular function (echocardiography, systolic time intervals), plasma renin activity and platelet ...

      Known for Angina Pectoris | Combined Alpha | Labetalol Therapy | Systemic Hypertension | Heart Rate
      KOL-Index: 13523

      BACKGROUND: There is a paucity of data regarding the complications and in-hospital mortality after catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease.

      OBJECTIVE: The purpose of this study was to determine the temporal trends in utilization, in-hospital mortality, and complications of catheter ablation of postinfarction VT in the United States.

      METHODS: We used the 2002-2011 Nationwide Inpatient Sample (NIS) database to identify all patients ≥18 ...

      Known for Catheter Ablation | United States | Hospital Mortality | Ventricular Tachycardia | Myocardial Infarction
      KOL-Index: 12884

      BACKGROUND: Prior studies have found that smokers undergoing thrombolytic therapy for ST-segment elevation myocardial infarction have lower in-hospital mortality than nonsmokers, a phenomenon called the "smoker's paradox." Evidence, however, has been conflicting regarding whether this paradoxical association persists in the era of primary percutaneous coronary intervention.

      METHODS AND RESULTS: We used the 2003-2012 National Inpatient Sample databases to identify all patients aged ...

      Known for Myocardial Infarction | Percutaneous Coronary | Segment Elevation | Hospital Smokers | Undergoing Primary
      KOL-Index: 12673

      OBJECTIVE: The objective of this study was to report on the prevalence, incidence and prognosis of left ventricular hypertrophy (LVH) on the electrocardiogram (ECG) in a cohort of ambulatory older men and women.

      DESIGN: A prospective, longitudinal study of 10 years duration with ECGs obtained at baseline and on an annual basis.

      SETTING AND PATIENTS: A community-based cohort study consisting of 459 subjects (aged 75-85, mean age 79 years).

      MEASUREMENTS: Baseline and follow up ECGs were ...

      Known for Ventricular Hypertrophy | Lvh Ecg | Cardiovascular Disease | Prevalence Prognosis | Prognostic Implications

      Key People For Angina Pectoris

      Top KOLs in the world
      #1
      Braunwald Braunwald
      myocardial infarction heart failure atrial fibrillation
      #2
      Stephen E Epstein
      hypertrophic cardiomyopathy angina pectoris coronary artery disease
      #3
      A'ttilio Maseri
      unstable angina myocardial infarction coronary artery
      #4
      Richard Gorlin
      coronary artery disease myocardial infarction angina pectoris
      #5
      Carl J Pepine
      coronary artery myocardial ischemia blood pressure
      #6
      Filippo Filippo
      myocardial infarction unstable angina acute coronary syndromes

      Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY. | Department of Cardiology, Westchester Medical Center, Valhalla, NY. | Department of Medicine, New York Medical College, Valhalla, NY 10595, USA. | Depart

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.